Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation...
Ascletis Pharma to Host Obesity Portfolio Webinar on April 2, 2025
HONG KONG, March 20, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces it will host an Obesity Portfolio Webinar on April 2, 2025, from 9:00 a.m. – 10:30 a.m. ET. The event will include a detailed discussion on Ascletis'...
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascending dose (MAD) c ohort 2 (weekly titrations of 2 mg, 10 mg, 20 mg , and 40 mg). - ASC30 oral once-daily tablet also...